Radiation oncology as a profession is in a period of retrenchment due to the economic crisis. There is also a growing demand from payors to show value for these treatments, said ASTRO President Anthony Zeitman, M.D. He says the technologies used need to undergo rigorous clinical testing to show what works best and what is most cost-effective. Part of ASTRO's push is for a national registry to help advance this data collection.
If you enjoy this content, please share it with a colleague
Related Content
Dec. 11, 2025 — Telix Pharmaceuticals Ltd. has announced a strategic clinical collaboration with Varian, a Siemens ...
Dec. 02, 2025 — Alpha Tau Medical Ltd., the developer of the alpha-radiation cancer therapy Alpha DaRT, has announced ...
Nov. 12, 2025 — On Nov. 11, Huntsman Cancer Institute at the University of Utah (the U) opened its first specialized ...
Nov. 12, 2025 — Siemens has announced plans to deconsolidate its remaining stake in Siemens Healthineers (currently ...
Nov. 11, 2025 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has released a position paper outlining ...
Nov. 10, 2025 — Researchers at Wayne State University and the Barbara Ann Karmanos Cancer Institute have developed a ...
Nov. 3, 2025 — RevealDx, a leader in the characterization of lung nodules, has introduced MDR Certification of RevealAI ...
Nov. 6, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, recently announced that Volpara ...
Nov. 3, 2025 — —A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 ...
Radiotherapy contributes to about 40% of all cancer cures but still lags behind systemic therapy in funding and ...
December 11, 2025 